Last reviewed · How we verify
Supplementation of ferric carboxymaltose
Supplementation of ferric carboxymaltose is a Small molecule drug developed by Medical University of Vienna. It is currently FDA-approved.
Ferric carboxymaltose, marketed by the Medical University of Vienna, is an iron supplement currently available in the market. The key composition patent expires in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the lack of disclosed revenue data, which may limit insights into its market performance and financial impact.
At a glance
| Generic name | Supplementation of ferric carboxymaltose |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
- The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department (PHASE4)
- EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY (PHASE1)
- IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study (PHASE2, PHASE3)
- Patient Blood Management In CARdiac sUrgical patientS
- Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression (PHASE4)
- Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia
- Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Supplementation of ferric carboxymaltose CI brief — competitive landscape report
- Supplementation of ferric carboxymaltose updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI